Leading Independent Proxy Advisory Firms ISS And Glass Lewis Recommend Mast Therapeutics Stockholders Vote "FOR" The Proposed Merger And Related Proposals
In its report, ISS stated, among other things, that1: "Support FOR the merger proposal is warranted given the positive market reaction to the deal, the strategic rationale, and the opportunity for shareholders to participate in any upside in the combined company's operations."
Commenting on the proxy advisors' reports,
The merger has been unanimously approved by the boards of directors of both companies and Mast urges its stockholders to vote "FOR" the merger and the other proposals set forth in the proxy statement/prospectus/ information statement dated
Mast stockholders should note that the merger proposal (Proposal 1), the reverse stock split proposal (Proposal 2) and the name change proposal (Proposal 3) must all be approved for the merger to be completed. If any of those proposals is not approved, the merger will not go forward. In addition, Proposals 2 and 3 must be approved by a majority of Mast's outstanding common stock as of the record date, so every vote in favor of these proposals is extremely important no matter how many or how few shares you own. Ownership of Mast shares is widely dispersed, and it is therefore important to have as many of the Mast stockholders as possible vote regardless of the number of shares owned.
THE MERGER WILL NOT GO FORWARD UNLESS
THE MERGER, REVERSE STOCK SPLIT AND NAME CHANGE PROPOSALS
ARE ALL APPROVED.
MAST STOCKHOLDERS – PLEASE VOTE TODAY!
Failure to vote or an abstention from voting will have the same effect as a vote "AGAINST" the merger and related proposals. All stockholders are asked to vote "FOR" all proposals as soon as possible.
If you are a Mast stockholder and you have questions or require assistance in submitting your proxy or voting your shares, please contact Mast's proxy solicitor:
ADVANTAGE PROXY, INC.
Toll Free: 1-877-870-8565
Additional Information about the Proposed Merger and Where to Find It
In connection with the proposed merger,
This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities in connection with the proposed merger shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.
Participants in the Solicitation
Mast and its directors and executive officers and Savara and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Mast and Savara in connection with the proposed transaction. Information regarding the special interests of these directors and executive officers in the proposed merger is included in the proxy statement/prospectus/information statement referred to above. Additional information regarding the directors and executive officers of Mast is also included in Mast's Annual Report on Form 10-K for the year ended
Forward Looking Statements
Mast and Savara caution you that statements in this press release that are not a description of historical fact are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances such as "expect," "intend," "plan," "anticipate," "believe," and "will," among others. Such statements include, but are not limited to, statements regarding the structure, timing and completion of the proposed merger; expectations regarding listing and trading of Mast's common stock on the NYSE MKT and of the combined organization's common stock on the
1 Permission to use quotation neither sought nor obtained.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/leading-independent-proxy-advisory-firms-iss-and-glass-lewis-recommend-mast-therapeutics-stockholders-vote-for-the-proposed-merger-and-related-proposals-300437640.html
Ioana C. Hone (email@example.com), 858-552-0866 Ext. 303